Zai Lab, a company in Zhangjiang, announces the listing of its product, Optune, in Hong Kong for the treatment of glioblastoma multiforme (GBM) on Feb 28. [Photo/WeChat account: zjpark]

Toripalimab, an emerging cancer therapy that boosts the immune system to help the body to target and kill tumors, developed by Zhangjiang's Junshi Biosciences, is the first self-developed anti-PD-1 treatment in China.

It was used in treatment at the Beijing Cancer Hospital for the first time on Feb 26, and will soon be available in 51 cities nationwide.

Another Zhangjiang company, Zai Lab, announced the listing of its product, Optune, in Hong Kong for the treatment of glioblastoma multiforme (GBM) on Feb 28.

The first and only tumor electric field treatment product approved by the US Food and Drug Administration (FDA), Optune has also been approved for GBM treatment in Europe, Japan and many other countries and regions.

The rapid development of Zhangjiang's pharmaceutical industry has drawn the attention of many global leading venture capital companies. The continuous financing is promoting R&D of new drugs by Zhangjiang's innovative pharmaceutical enterprises.

Additionally, with the Shanghai Center for Drug Safety Evaluation and Research and the Zhangjiang Cross-border Scientific Innovation Supervision Service Center being settled in Zhangjiang, relevant enterprises have easy access to all-round services.